Differentiated Thyroid Gland Carcinoma Clinical Trial
Official title:
Evaluation of F-18 Tetrafluoroborate (18F-TFB) PET/CT in Patients With Differentiated Thyroid Cancer
This phase II study evaluates F-18 tetrafluoroborate (18F-TFB) PET/CT scan in patients with differentiated thyroid cancer. Diagnostic imaging is necessary for planning treatment, monitoring therapy response, and identifying sites of recurrent or metastatic disease in differentiated thyroid cancer. 18F-TFB PET/CT may accurately detect recurrent and metastatic thyroid cancer lesions, with the potential to provide information for patient management that is better than the current standard of care imaging practices.
PRIMARY OBJECTIVES: I. Evaluate fluorine F 18 tetrafluoroborate (18F-TFB) positron emission tomography (PET)/computed tomography (CT) imaging in patients with intermediate or high risk differentiated thyroid cancer (DTC) and compare to the current clinical standard. II. Assess the impact of 18F-TFB PET/CT on clinical management. OUTLINE: Patients receive fluorine F 18 tetrafluoroborate intravenously (IV) and undergo PET/CT scan on study. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02592356 -
Effect of Cabozantinib S-Malate or Lenvatinib Mesylate on Weight and Body Composition in Patients With Metastatic Endocrine Cancer
|
N/A | |
| Terminated |
NCT03506048 -
Lenvatinib and Iodine Therapy in Treating Patients With Radioactive Iodine-Sensitive Differentiated Thyroid Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT03914300 -
Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT00381641 -
Sunitinib Malate in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery
|
Phase 2 |